萘丁美酮和尼美舒利治疗类风湿关节炎疗效和安全性的比较

目的 :比较 2种非甾类消炎药 (NSAIDs)萘丁美酮和尼美舒利治疗类风湿关节炎 (RA)的疗效和安全性。方法 :6 2例活动性RA病人分为 2组 ,萘丁美酮组 (治疗组 ) 30例 ,给予萘丁美酮 5 0 0mg ,po ,bid ;尼美舒利组 (对照组 ) 32例 ,给予尼美舒利10 0mg ,po ,bid。 2组均给药 4wk。受试前后观察临床和实验室指标的变化。结果 :萘丁美酮组总有效率为 87% ,尼美舒利组总有效率为 83% ,P >0 .0 5。与萘丁美酮治疗有关的不良反应包括 :恶心、胃烧灼感、反酸和嗜睡各 1例 ,不良反应率13% ;尼美舒利组不良反应率为 19% ,P >0 .0 5。结论 :萘丁美酮对RA的疗效和不良反应的发生率均与尼美舒利相似 ,是一种较为有效、安全且服用方便的NSAIDs。

A comparison between nabumetone and nimesulide on efficacy and safety in treatment of rheumatoid arthritis

AIM: To compare the efficacy and safety of nabumetone with that of nimesulide in the treatment of rheumatoid arthritis (RA). METHODS: Sixty two active RA patients were divided into two groups: thirty patients of nabumetone group were treated with nabumetone 500 mg, po bid×4 wk; thirty two patients of nimesulide group were treated with nimesulide 100 mg, po bid×4 wk. Clinical and laboratory parameters were observed pre and post treatment. RESULTS: The total effective rate of nabumetone and nimesulide group for RA was 87% and 83% ( P >0.05), respectively. The adverse reactions related to nabumetone were nausea, heartburn, acid reflux and drowsiness. The incidence of each clinical adverse reaction was similar among the treatment groups. The adverse reaction rate was 13% in nabumetone group, while 19% in nimesulide group( P >0.05). CONCLUSION: Nabumetone is effective and safe in treating RA, showing comparable clinical efficacy and incidence of adverse reaction to that of nimesulide.